Fludeoxyglucose (18F) — Drug Intelligence | 25 EU Trials

Filter these 25 trials by condition, phase, country and more.

Open in Search →

25 Registered trials

13 Recruiting

9 Completed trials

17 Sponsors

14 Countries

Phase III

Phase II

Phase IV

Phase III: 7 Phase II/III: 1 Phase II: 12 Phase I/II: 1 Phase IV: 3 Phase I (FiH): 1

Oversight events:

1 temporary halt 1 urgent safety measure 1 unexpected event across 3 trials

View oversight register →

Indications tested

Neuroendocrine carcinoma metastatic 2 Neuroendocrine carcinoma 2 Langerhans' cell histiocytosis 1 Ovarian cancer 1 Aortic stenosis 1 Gastric cancer 1 Langerhans cell sarcoma 1 Follicular lymphoma 1 Rosai-Dorfman syndrome 1 Erdheim-Chester disease 1 Huntington's disease 1 Marginal zone lymphoma 1

Sponsors using this IMP

Aalborg University Hospital 3 Centre Hospitalier Universitaire De Nantes 3 Rigshospitalet 3 Amsterdam UMC Stichting 2 Odense University Hospital 2 Academisch Ziekenhuis Maastricht 1 AskBio France 1 Barcelonabeta Brain Research Center 1 Centre Hospitalier Regional Et Universitaire De Brest 1 F. Hoffmann-La Roche AG 1 Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer 1 Institut Jules Bordet 1

All trials

25 total

Post-INFECT: Investigating Neuroinflammation and its effects in post-COVID syndrome Pending

2025-522349-23-00 Phase III 1 country Amsterdam UMC Stichting
Improved baseline staging with 68Ga-FAPI-46 PET in non-small cell lung cancer – a pilot study Pending

2025-523032-39-00 Phase II 1 country Academisch Ziekenhuis Maastricht
Application of radiomics for diagnosis and follow-up of cardiovascular device infections: PREDICT study Pending

2025-524624-21-00 Phase IV 1 country Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques Augus…
Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and of glucose metabolism with 18F-FDG PET in individuals enrolled… Recruiting

2024-519961-23-00 Phase IV 1 country Barcelonabeta Brain Research Center
Evaluating the roLe of Multiplexed PET Imaging in the detection and staging of hepatocellulaR carcinoma and gAstro-entero-pancreatic tumors:… Recruiting

2024-519505-35-00 Phase III 1 country Centre Hospitalier Universitaire De Nantes
18F-FDG versus 68Ga-FAPI-46 as PET tracer in ER-positive breast cancer - a pilot study Recruiting

2023-508066-15-01 Phase II 1 country University Hospital Maastricht
[68Ga]Ga-FAPI PET/CT for response evaluation during immune checkpoint inhibitor therapy in malignant melanoma Recruiting

2023-509549-11-00 Phase II 1 country Rigshospitalet
FDG-PET/CT versus conventional CT for response monitoring in metastatic breast cancer: a multicenter randomized clinical trial (MONITOR-RCT) Recruiting

2023-508591-11-00 Phase III 3 countries Odense University Hospital
FAPI PET in Pleural Mesothelioma Recruiting

2024-514301-62-00 Phase II 1 country Aalborg University Hospital
Impact of local tissue inflammation on intramyocardial conduction pathways post percutaneous valve : evaluation by positron emission tomogra… Recruiting

2024-514587-44-00 Phase II 1 country Centre Hospitalier Regional Et Universitaire De Brest
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Phase III 6 countries Lysarc
Immune-Related Rheumatological and neurological Adverse Events study. Recruiting

2024-516631-27-00 Phase II 1 country Stichting Amsterdam UMC
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients with Neuroendocrine Neoplasms Recruiting

2024-516156-18-00 Phase II 1 country Rigshospitalet
Phase IIa Clinical Trial: Feasibility Study on Non-Invasive Simultaneous Hyperpolarized [1-13C]Pyruvate Magnetic Resonance Spectroscopy and … Recruiting

2024-516131-28-00 Phase II 1 country Rigshospitalet
Examination of the molecular profile in adolescent patients with histiocytic cell hyperplasia, and if a specific mutation is detected, its m… Recruiting

2024-515895-11-00 Phase IV 1 country Instytut Matki I Dziecka
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies Recruiting

2023-504931-42-00 Phase II 10 countries Merck Sharp & Dohme LLC
Phase I/II Safety and Tolerability Study of striatal administration of AB-1001 in adult subjects with Early Manifest Huntington's Disease (H… Ended

2024-510895-18-00 Phase I (FiH) 1 country AskBio France
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Ved… Ended

2023-506986-74-00 Phase I/II 2 countries F. Hoffmann-La Roche AG
Patient reported outcomes in term of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy … Ended

2023-506258-19-00 Phase III 1 country Institut Jules Bordet
FDG-PET/CT versus conventional CT for response monitoring in metastatic breast cancer: A pilot study for a randomized clinical trial (MONITO… Ended

2023-506550-20-00 Phase II/III 1 country Odense University Hospital
[68Ga]Ga-PentixaFor-PET imaging for staging of marginal zone lymphoma Ended

2022-500918-25-00 Phase III 5 countries Pentixapharm AG
68Ga-FAPI PET/CT: The Diagnostic Accuracy for Primary Staging and Re-staging after Chemotherapy in Patients with Gastric and Gastro-Esophage… Ended

2023-505916-40-01 Phase II 1 country Aalborg University Hospital
Contribution of PET (positron emission tomography) scans for the preoperative assessment of symptomatic endometriosis lesions: TEP-ENDORUN Ended

2024-520423-88-00 Phase III 1 country Centre Hospitalier Universitaire De La Reunion
68Ga-FAPI PET/CT: The Diagnostic Accuracy for Primary Staging and Re-staging of Patients with Ovarian Cancer Ended

2023-505938-98-00 Phase II 1 country Aalborg University Hospital

Showing 1–24 of 25 trials

← All drugs A–Z